Lymphoma, T-Cell × Dermatologic × Clear all
NCT02978625 2026-03-18

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
NCT01787409 2025-12-30

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Mayo Clinic

Phase NA Active not recruiting
565 enrolled
NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Mayo Clinic

Phase 1 Recruiting
46 enrolled
NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
127 enrolled
NCT05978141 2025-05-21

A Registry for People With T-cell Lymphoma

Memorial Sloan Kettering Cancer Center

Recruiting
1,000 enrolled
NCT02652715 2019-11-15

Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma

Mayo Clinic

Phase NA Completed
29 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT00608361 2015-07-02

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
NCT01129180 2013-12-03

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
8 enrolled